Hacked by islam_Bey imhatimi.org

Dishman Pharmaceuticals & Chemicals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 22, 2008, inter alia, has taken the following decisions:

1. The Board has recommended the final dividend @ 50% for the financial year 2007-08 on the paid-up equity share capital of the Company.

2. The Board has increased the Remuneration of Mrs. Deohooti J Vyas, whole-time Director of the Company w.e.f. June 01, 2008 upon the recommendation of Remuneration Committee held May 22, 2008.

3. The Board has also decided for the payment of Remuneration by way of Commission in terms of the provisions of the Companies Act, 1956, to the Non-Executive Director(s) of the Company subject to approval of the Members in the ensuing Annual General Meeting.

Further, the Company announces that it has invested Australian Dollar 1,00,000 in the equity into Dishman Australasia Pty Ltd., which has been established as wholly owned subsidiary of the Company in Australia.

Dishman Pharmaceuticals & Chemicals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 22, 2008, inter alia, to consider and take on record the Audited Financial Results of the Company for the year ended March 31, 2008; to recommend Final Dividend, if any; to approve Notice, Directors’ Report etc.; to fix the dates of Book Closure & Annual General Meeting etc.

Dishman Pharmaceuticals & Chemicals Ltd has informed BSE that the Company has completed installation of three API (Active Pharmaceutical Ingredient) Units at its Bavla facility at around cost of Rs 150 Crores as “Project Taurus”.

The last (Fourth) API facility will be dedicated for cytotoxic and cytotoxic compounds, such as Anti-Cancer Drugs. Hormones, etc. This facility will be ready for commissioning before the end of the current calendar year.

Dishman Pharmaceuticals & Chemicals Ltd has informed BSE that the Board of Directors of the Company on April 28, 2008, has allotted 10,13,023 equity shares of Rs 2/- each of the Company at a premium of Rs 170/- per equity share upon exercise of option by a bondholder for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 4,000,000 into the equity shares of the Company.

Consequently, the paid-up equity share capital of the Company has increased from 79684113 equity shares of Rs 2/- each to 80697136 equity shares of Rs 2/- each.

Dishman Pharmaceuticals & Chemicals Ltd has informed BSE that the Board of Directors of the Company on March 17, 2008, has allotted 10,13,023 equity shares of Rs 2/- each of the Company at a premium of Rs 170/- per equity share upon exercise of option for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 4,000,000, into the equity shares of the Company, by a bondholder.

Consequently, the paid-up equity share capital of the Company has increased from 78671090 equity shares of Rs 2/- each to 79684113 equity shares of Rs 2/- each.